ArticleBioMed research international2022
Performance Analysis of Ovarian Cancer Detection and Classification for Microarray Gene Data.
Article in BioMed research international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Improved Prediction of Ovarian Cancer Using Ensemble Classifier and Shaply Explainable AI.Cancers · 2023Article
- Enhancement of Classifier Performance Using Swarm Intelligence in Detection of Diabetes from Pancreatic Microarray Gene Data.Biomimetics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most common gynecologic cancer, behind cervical and uterine, is ovarian cancer. Ovarian cancer is a severe concern for women. Abnormal cells form and spread throughout the body. Ovarian cancer microarray data can diagnose and prognosis. Typically, ovarian cancer microarray data contains tens of thousands of genes. In order to reduce computational complexity, selecting the most critical genes or attributes in the entire dataset is necessary. Because microarray datasets have limited samples and many characteristics, classifier detection lags. So, dimensionality reduction measures are essential to protect disease classification genes. In this research, initially the ANOVA method is used for gene selection and then two clustering-based and three transform-based feature extraction methods, namely, Fuzzy C Means, Softmax Discriminant Algorithm (SDA), Hilbert Transform, Fast Fourier Transform (FFT), and Discrete Cosine Transform (DCT), respectively, are used to select relevant genes further. Six classifiers further classify the features as normal and abnormal. The NLR classifier gives the highest accuracy for SDA features at 92%, and KNN gives the lowest accuracy of 55% for SDA, Hilbert, and DCT features. With correlation distance feature selection, the NLR classifier attains the lowest accuracy of 53%, and the highest accuracy of 88% is obtained by the GMM classifier.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.